Clinical Trial Update: Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) [Phase 4]

View source ↗

Summary

Phase 4, double-blind trial assessing CT lung density decline in adults with alpha-1 antitrypsin deficiency treated with Respreeza or Zemaira weekly for 3 years…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Emphysema

Drugs mentioned

• Respreeza (alpha-1 proteinase inhibitor (human))
• Zemaira (human alpha-1 proteinase inhibitor)

Snippet

Sponsor: CSL Behring | Conditions: Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency | Phase 4 | Status: NOT_YET_RECRUITING